Cubist Systematic Strategies’s ImmunityBio IBRX Stock Holding History

Cubist Systematic Strategies’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-56,968	Closed	-$306K	–	3454
2024 Q1	$306K	Buy	+56,968	New	+$258K	﹤0.01%	2865
2023 Q2	–	Sell	-152,355	Closed	-$277K	–	3879
2023 Q1	$277K	Buy	+152,355	New	+$474K	﹤0.01%	3043
2022 Q4	–	Sell	-20,700	Closed	-$103K	–	4399
2022 Q3	$103K	Sell	20,700 -56,656	-73%	-$258K	﹤0.01%	4008
2022 Q2	$288K	Sell	77,356 -46,546	-38%	-$187K	﹤0.01%	3461
2022 Q1	$695K	Buy	123,902 +105,010	+556%	+$644K	0.01%	2309
2021 Q4	$115K	Sell	18,892 -10,010	-35%	-$75.2K	﹤0.01%	3170
2021 Q3	$282K	Sell	28,902 -129,778	-82%	-$1.43M	﹤0.01%	2391
2021 Q2	$2.27M	Buy	+158,680	New	+$2.62M	0.03%	1004
2020 Q4	–	Sell	-18,974	Closed	-$132K	–	2619
2020 Q3	$132K	Buy	+18,974	New	+$189K	﹤0.01%	2238

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cubist Systematic Strategies's IBRX Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of ImmunityBio (IBRX) in Q2 2024, closing a stake of 56,968 shares — an estimated $306K sold.

Cubist Systematic Strategies first reported a position in IBRX in Q3 2020 and held it in 9 quarters. The position peaked at $2.27M in Q2 2021. 193 funds tracked by Wall St. Rank hold IBRX as of Q2 2024.

Cubist Systematic Strategies reported no remaining ImmunityBio position as of Q2 2024 after selling out during the quarter.
Cubist Systematic Strategies sold 56,968 ImmunityBio shares in Q2 2024, an estimated $306K.
Cubist Systematic Strategies first reported a position in ImmunityBio in Q3 2020 and held it in 9 quarters.
Cubist Systematic Strategies's ImmunityBio position peaked at $2.27M in Q2 2021.
193 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.